Proposal for Clinical Management of Nodules Diagnosed As Atypia of Undetermined Significance Via Thyroid Fine-Needle Aspiration Cytology in the Absence of Molecular Testing

Overview

Journal Cytopathology

Date 2025 Jan 11

PMID 39794920

Authors

Ayana Suzuki

Mitsuyoshi Hirokawa

Makoto Kawakami

Takumi Kudo

Akira Miyauchi

Takashi Akamizu

Affiliations

Soon will be listed here.

Abstract

Objective: Molecular testing is recommended for risk stratification of atypia of undetermined significance (AUS) nodules in the USA; however, it is not routinely performed in some countries owing to limited availability and affordability. Here, we propose a risk stratification algorithm for AUS nodules when molecular testing is unavailable.

Methods: We examined 304 (4.3%) AUS nodules among 7073 thyroid fine-needle aspiration cytology specimens examined at Kuma Hospital from January 2020 to December 2020. Clinical data were obtained from the medical records of Kuma Hospital.

Results: AUS with nuclear atypia and AUS-other each accounted for half of the total AUS nodules. The repeat aspiration rate was 19.7%; 61.7% of the nodules were reclassified as benign or malignant upon repeat aspiration. Resection rate and overall risk of malignancy (ROM) were 32.6% and 12.8%, respectively. Architectural atypia showed the lowest (1.1%) overall ROM in the AUS nodules. For AUS with nuclear atypia, nodules ≤ 10 mm in size showed significantly lower overall ROM than those of > 10 mm, and nodules with ultrasonographically low suspicion showed significantly lower overall ROM than those with intermediate to high suspicion. AUS nodules with atypical lymphoid cells, possible medullary thyroid carcinoma, or possible parathyroid lesion were confirmed using flow cytometry, biochemical testing using needle washout fluid or immunocytochemistry, respectively.

Conclusions: Our proposed clinical management algorithm for each subdivision according to cytological findings, based on repeat aspiration rates, ROM, ultrasound findings and results of ancillary tests except for molecular testing, should be useful for the clinical management of AUS nodules.

References

Suzuki A, Hirokawa M, Kanematsu R, Tanaka A, Yamao N, Higuchi M . Fine-needle aspiration of parathyroid adenomas: Indications as a diagnostic approach. Diagn Cytopathol. 2020; 49(1):70-76. PMC: 7754293. DOI: 10.1002/dc.24595. View

Gong Y, Joseph T, Sneige N . Validation of commonly used immunostains on cell-transferred cytologic specimens. Cancer. 2005; 105(3):158-64. DOI: 10.1002/cncr.21063. View

Hathi K, Rahmeh T, Munro V, Northrup V, Sherazi A, Chin C . Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center - a retrospective cohort study. J Otolaryngol Head Neck Surg. 2021; 50(1):58. PMC: 8504068. DOI: 10.1186/s40463-021-00530-0. View

Trimboli P, DAurizio F, Tozzoli R, Giovanella L . Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clin Chem Lab Med. 2016; 55(7):914-925. DOI: 10.1515/cclm-2016-0543. View

Oda H, Miyauchi A, Ito Y, Sasai H, Masuoka H, Yabuta T . Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr J. 2016; 64(1):59-64. DOI: 10.1507/endocrj.EJ16-0381. View

Lee L, How J, Tabah R, Mitmaker E . Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. J Clin Endocrinol Metab. 2014; 99(8):2674-82. DOI: 10.1210/jc.2014-1219. View

Kaliszewski K, Diakowska D, Rzeszutko M, Nowak L, Tokarczyk U, Rudnicki J . Atypia and Follicular Lesions of Undetermined Significance in Subsequent Biopsy Result: What Clinicians Need to Know. J Clin Med. 2021; 10(14). PMC: 8303631. DOI: 10.3390/jcm10143082. View

Takada N, Hirokawa M, Suzuki A, Higuchi M, Kuma S, Miyauchi A . Diagnostic value of GATA-3 in cytological identification of parathyroid tissues. Endocr J. 2016; 63(7):621-6. DOI: 10.1507/endocrj.EJ15-0700. View

Jan I, Lee Y, Wang C, Cheng T, Wang C, Chang T . The surgery and repeat aspiration outcomes of the atypia of undetermined significance/follicular lesion of undetermined significance category in The Bethesda System for Reporting Thyroid Cytopathology. Asian J Surg. 2018; 42(1):144-147. DOI: 10.1016/j.asjsur.2018.02.008. View

10.

Seagrove-Guffey M, Hatic H, Peng H, Bates K, Odugbesan A . Malignancy rate of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid nodules undergoing FNA in a suburban endocrinology practice: A retrospective cohort analysis. Cancer Cytopathol. 2018; 126(10):881-888. DOI: 10.1002/cncy.22054. View

11.

Wu J, Lam R, Levin M, Rao J, Sullivan P, Yeh M . Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery. 2015; 159(1):118-26. DOI: 10.1016/j.surg.2015.05.035. View

12.

. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment. Ont Health Technol Assess Ser. 2022; 22(2):1-111. PMC: 9095064. View

13.

Kholova I, Ludvikova M . Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage?. Acta Cytol. 2014; 58(4):319-29. DOI: 10.1159/000366498. View

14.

Ding J, Jiang L, Fang J, Jiang Y, Zhu Y, Hua T . Predictors for malignancy risk in subcentimeter thyroid nodules categorized as atypia/follicular lesion of undetermined significance by fine needle aspiration. Sci Rep. 2019; 9(1):14973. PMC: 6802379. DOI: 10.1038/s41598-019-50597-z. View

15.

Suzuki A, Hirokawa M, Takada N, Higuchi M, Ito A, Yamao N . Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan. Endocr J. 2017; 64(11):1099-1104. DOI: 10.1507/endocrj.EJ17-0238. View

16.

Onder S, Firat P, Ates D . The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories. Cytopathology. 2013; 25(3):177-84. DOI: 10.1111/cyt.12091. View

17.

Oczko-Wojciechowska M, Kotecka-Blicharz A, Krajewska J, Rusinek D, Barczynski M, Jarzab B . European perspective on the use of molecular tests in the diagnosis and therapy of thyroid neoplasms. Gland Surg. 2020; 9(Suppl 2):S69-S76. PMC: 7044080. DOI: 10.21037/gs.2019.10.26. View

18.

Kihara M, Hirokawa M, Kudo T, Hayashi T, Yamamoto M, Masuoka H . Calcitonin measurement in fine-needle aspirate washout fluid by electrochemiluminescence immunoassay for thyroid tumors. Thyroid Res. 2018; 11:15. PMC: 6208047. DOI: 10.1186/s13044-018-0059-4. View

19.

Suzuki A, Hirokawa M, Kanematsu R, Tanaka A, Yamao N, Higuchi M . B-cell to T-cell ratio as a novel indicator in flow cytometry in the diagnosis of thyroid lymphoma. Endocr J. 2021; 69(3):291-297. DOI: 10.1507/endocrj.EJ21-0451. View

20.

Hirokawa M, Suzuki A, Higuchi M, Hayashi T, Kuma S, Ito Y . The Japanese reporting system for thyroid aspiration cytology 2019 (JRSTAC2019). Gland Surg. 2020; 9(5):1653-1662. PMC: 7667058. DOI: 10.21037/gs-2019-catp-22. View